Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GNK 301

Next Previous
Search
Drug Profile

GNK 301

Alternative Names: Anti-HERV-K mab - GeNeuro Pharma; GN-K01; GNK-301; pHERV-K Env antibody - GeNeuro Pharma

Latest Information Update: 22 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GeNeuro
  • Developer GeNeuro; National Institute of Neurological Disorders and Stroke
  • Class Monoclonal antibodies
  • Mechanism of Action Viral envelope protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Amyotrophic lateral sclerosis

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis

Most Recent Events

  • 22 Apr 2025 GNK 301 is still in preclinical trials for Amyotrophic lateral sclerosis in US (GeNeuro Pharma pipeline, April 2025)
  • 28 Jan 2025 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA (Parenteral)
  • 06 Dec 2024 Pharmacodynamics data from a preclinical studies in Amyotrophic lateral sclerosis released by GeNeuro

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top